Literature DB >> 20950615

IL28B and the control of hepatitis C virus infection.

Ashwin Balagopal1, David L Thomas, Chloe L Thio.   

Abstract

Treatment-induced control and spontaneous clearance of hepatitis C virus (HCV) infection are affected by various host factors. Polymorphisms in the region of the gene IL28B are associated with HCV clearance, implicating the gene product, interferon (IFN)-λ3, in the immune response to HCV. Although it is not clear how the IL28B haplotype affects HCV clearance, IFN-λ3 up-regulates interferon-stimulated genes, similar to IFN-α and IFN-β but via a different receptor. There is also evidence that IFN-λ3 affects the adaptive immune response. The IL28B genotype can be considered, along with other factors, in predicting patient responses to therapy with pegylated IFN-α and ribavirin. We review the genetic studies that uncovered the association between IL28B and HCV clearance, the biology of IFN-λ3, the clinical implications of the genetic association, and areas of future research.
Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20950615      PMCID: PMC3072961          DOI: 10.1053/j.gastro.2010.10.004

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  45 in total

1.  Viral infections activate types I and III interferon genes through a common mechanism.

Authors:  Kazuhide Onoguchi; Mitsutoshi Yoneyama; Azumi Takemura; Shizuo Akira; Tadatsugu Taniguchi; Hideo Namiki; Takashi Fujita
Journal:  J Biol Chem       Date:  2007-01-04       Impact factor: 5.157

2.  Progression of liver fibrosis among injection drug users with chronic hepatitis C.

Authors:  Lucy E Wilson; Michael Torbenson; Jacquie Astemborski; Hawazin Faruki; Charles Spoler; Rudra Rai; Shruti Mehta; Gregory D Kirk; Kenrad Nelson; Nezam Afdhal; David L Thomas
Journal:  Hepatology       Date:  2006-04       Impact factor: 17.425

Review 3.  IFN-lambda: novel antiviral cytokines.

Authors:  Nina Ank; Hans West; Søren R Paludan
Journal:  J Interferon Cytokine Res       Date:  2006-06       Impact factor: 2.607

4.  Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

Authors:  Limin Chen; Ivan Borozan; Jordan Feld; Jing Sun; Laura-Lee Tannis; Catalina Coltescu; Jenny Heathcote; Aled M Edwards; Ian D McGilvray
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

5.  Lambda interferon inhibits hepatitis B and C virus replication.

Authors:  Michael D Robek; Bryan S Boyd; Francis V Chisari
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes.

Authors:  Sean E Doyle; Heidi Schreckhise; Kien Khuu-Duong; Katherine Henderson; Robert Rosler; Harold Storey; Lena Yao; Hong Liu; Fariba Barahmand-pour; Pallavur Sivakumar; Chung Chan; Carl Birks; Don Foster; Christopher H Clegg; Perdita Wietzke-Braun; Sabine Mihm; Kevin M Klucher
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

7.  Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.

Authors:  Tobias Marcello; Arash Grakoui; Giovanna Barba-Spaeth; Erica S Machlin; Sergei V Kotenko; Margaret R MacDonald; Charles M Rice
Journal:  Gastroenterology       Date:  2006-10-01       Impact factor: 22.682

8.  Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo.

Authors:  Nina Ank; Hans West; Christina Bartholdy; Kristina Eriksson; Allan R Thomsen; Søren R Paludan
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

9.  Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response.

Authors:  W J Jordan; J Eskdale; S Srinivas; V Pekarek; D Kelner; M Rodia; G Gallagher
Journal:  Genes Immun       Date:  2007-03-15       Impact factor: 2.676

10.  A whole-genome association study of major determinants for host control of HIV-1.

Authors:  Jacques Fellay; Kevin V Shianna; Dongliang Ge; Sara Colombo; Bruno Ledergerber; Mike Weale; Kunlin Zhang; Curtis Gumbs; Antonella Castagna; Andrea Cossarizza; Alessandro Cozzi-Lepri; Andrea De Luca; Philippa Easterbrook; Patrick Francioli; Simon Mallal; Javier Martinez-Picado; José M Miro; Niels Obel; Jason P Smith; Josiane Wyniger; Patrick Descombes; Stylianos E Antonarakis; Norman L Letvin; Andrew J McMichael; Barton F Haynes; Amalio Telenti; David B Goldstein
Journal:  Science       Date:  2007-07-19       Impact factor: 47.728

View more
  100 in total

1.  Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort.

Authors:  Fuat Kurbanov; Mohamed Abdel-Hamid; Rachel Latanich; Jacquie Astemborski; Mostafa Mohamed; Nabiel Mh Mikhail; Mai El-Daly; Sherif El-Kafrawy; David L Thomas; Chloe L Thio
Journal:  J Infect Dis       Date:  2011-09-20       Impact factor: 5.226

Review 2.  The genetic theory of infectious diseases: a brief history and selected illustrations.

Authors:  Jean-Laurent Casanova; Laurent Abel
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-05-29       Impact factor: 8.929

3.  Reply: To PMID 23873583.

Authors:  Brian L Pearlman; Carole M Ehleben
Journal:  Hepatology       Date:  2014-04-28       Impact factor: 17.425

4.  Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians.

Authors:  Zainab A Zakaria; Susanne Knapp; Mohamed Hashem; Hassan Zaghla; Mark Thursz; Imam Waked; Sayed Abdelwahab
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

5.  IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association.

Authors:  Fatma M Shebl; Ruth M Pfeiffer; Dianna Buckett; Brian Muchmore; Sabrina Chen; Myhanh Dotrang; Ludmila Prokunina-Olsson; Brian R Edlin; Thomas R O'Brien
Journal:  J Infect Dis       Date:  2011-10-19       Impact factor: 5.226

6.  Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.

Authors:  Alan S Wang; Ruth M Pfeiffer; Timothy R Morgan; Thomas R O'Brien
Journal:  Hepatology       Date:  2014-04-14       Impact factor: 17.425

Review 7.  Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions.

Authors:  Sreedhar Chinnaswamy
Journal:  J Interferon Cytokine Res       Date:  2014-02-20       Impact factor: 2.607

8.  Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes.

Authors:  M Michele Manos; Chanda K Ho; Rosemary C Murphy; Valentina A Shvachko
Journal:  Patient       Date:  2013       Impact factor: 3.883

9.  Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.

Authors:  Etienne Patin; Zoltán Kutalik; Julien Guergnon; Stéphanie Bibert; Bertrand Nalpas; Emmanuelle Jouanguy; Mona Munteanu; Laurence Bousquet; Laurent Argiro; Philippe Halfon; Anne Boland; Beat Müllhaupt; David Semela; Jean-François Dufour; Markus H Heim; Darius Moradpour; Andreas Cerny; Raffaele Malinverni; Hans Hirsch; Gladys Martinetti; Vijayaprakash Suppiah; Graeme Stewart; David R Booth; Jacob George; Jean-Laurent Casanova; Christian Bréchot; Charles M Rice; Andrew H Talal; Ira M Jacobson; Marc Bourlière; Ioannis Theodorou; Thierry Poynard; Francesco Negro; Stanislas Pol; Pierre-Yves Bochud; Laurent Abel
Journal:  Gastroenterology       Date:  2012-07-27       Impact factor: 22.682

Review 10.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.